Table 2.

Response rate based on IRAC assessment (IWRC 1999)^a (mITT Population)

			Immunohistochemistry				Gene expression profiling
	Overall		GCB		Non-GCB		GCB		ABC
	Len n = 51	IC n = 51	Len n = 23	IC n = 25	Len n = 28	IC n = 26	Len n = 14	IC n = 16	Len n = 11	IC n = 16
ORR, n (%)	14 (27.5)	6 (11.8)	6 (26.1)	3 (12.0)	8 (28.6)	3 (11.5)	3 (21.4)	2 (12.5)	5 (45.5)	3 (18.8)
[95% CI]b	[15.9–41.7]	[4.4–23.9]	[10.2–48.4]	[2.5–31.2]	[13.2–48.7]	[2.4–30.2]	[4.7–50.8]	[1.6–38.3]	[16.7–76.6]	[4.0–45.6]
P valuec	0.079		0.279		0.179		0.642		0.206
CRd, n (%)	5 (9.8)	1 (2.0)	1 (4.3)	0 (0.0)	4 (14.3)	1 (3.8)	1 (7.1)	0 (0.0)	3 (27.3)	1 (6.3)
PR, n (%)	9 (17.6)	5 (9.8)	5 (21.7)	3 (12.0)	4 (14.3)	2 (7.7)	2 (14.3)	2 (12.5)	2 (18.2)	2 (12.5)
SD, n (%)	13 (25.5)	11 (21.6)	5 (21.7)	7 (28.0)	8 (28.6)	4 (15.4)	4 (28.6)	3 (18.8)	2 (18.2)	3 (18.8)
PD/death, n (%)	24 (47.1)	33 (64.7)	12 (52.2)	14 (56.0)	12 (42.9)	19 (73.1)	7 (50.0)	11 (68.8)	4 (36.4)	10 (62.5)
Unknown, n (%)	0 (0.0)	1 (2.0)	0 (0.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
PFS, weeks	13.6	7.9	10.1	9.0	15.1	7.1	13.2	7.1	82.0	6.2
HR (95% CI)	0.64 (0.41-0.99)		0.82 (0.43–1.57)		0.50 (0.27-0.92)		0.77 (0.35–1.68)		0.44 (0.15–1.23)
P value	0.041		0.550		0.021		0.506		0.105
OS, weeks	31.0	24.6	30.0	24.9	32.3	20.4	30.0	20.1	108.4	18.6
HR (95% CI)	0.91 (0.59–1.41)		1.23 (0.65–2.34)		0.70 (0.38–1.30)		1.12 (0.52–2.42)		0.47 (0.17–1.33)
P value	0.673		0.526		0.253		0.767		0.144

^amITT population; defined as all randomized patients who had confirmed DLBCL and GCB or non-GCB subtype diagnosis and received ≥1 dose of study drug.

^bExact CI based on binomial distribution.

^cP value derived from the Fisher exact test.

^dNo CR unconfirmed observed.

Abbreviation: Len, lenalidomide